FDA approves new anti-obesity drug that will compete with Wegovy | ET REALITY

[ad_1]

The Food and Drug Administration on Wednesday approved an anti-obesity drug from the company Eli Lilly that will be a direct competitor to the very popular Wegovy.

The drug is called tirzepatide and will be sold under the name Zepbound. It joins a class of new drugs that are transforming weight loss and obesity, a condition that affects 100 million American adults and is linked to a spectrum of diseases including diabetes, heart disease, sleep apnea, liver disease , kidney diseases and joint pain.

Patients using tirzepatide lost an average of 18 percent of their body weight in a drug trial when taken at its highest dose. This compares to Wegovy, made by Novo Nordisk, which produced an average weight loss of 15 percent.

The FDA approved Zepbound for people with obesity and for those who are overweight and have an obesity-related condition, such as heart disease.

Tirzepatide is already approved for diabetes under the brand name Mounjaro, where it competes with Novo Nordisk’s diabetes drug semaglutide, better known as Ozempic. But until now Novo Nordisk’s Wegovy, which is also based on semaglutide, was the only approved drug that could safely cause substantial weight loss in people with obesity only.

In a news release, Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders and Obesity at the FDA’s Center for Drug Evaluation and Research, said: “In light of the increasing rates of obesity and overweight In the United States, the current situation Approval addresses an unmet medical need.”

“Just a few years ago, it would be difficult to imagine two drugs like semaglutide and tirzepatide leading to weight loss that was previously only seen when people underwent bariatric surgery,” said Susan Yanovski, co-director of the research office of obesity at the National Institute of Diabetes and Digestive and Kidney Diseases, referring to a surgical treatment that had been shown to be effective for obesity.

Leave a Comment